Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog

Table 1

Comparison of mean ± SE percent change in BMD from baseline to final in BMD (gm/cm²) between two groups. A two-sided significance level of 0.05 is used for a two-sample 𝑡-test.

		Placebo	Zoledronic acid	P-value
L1-L4 vertebrae	𝑁	14	16	.003
	Baseline	0.946 (0.052)	0.928 (0.030)
	Final	0.944 (0.042)	1.000 (0.031)
	Mean % change	+0.82 (1.7)	+7.93 (1.4)
Left total hip	𝑁	13	16	.278
	Baseline	0.888 (0.027)	0.868 (0.023)
	Final	0.893 (0.024)	0.889 (0.029)
	Mean % change	+0.71 (1.1)	+2.27 (0.92)
Left femoral neck	𝑁	13	16	.009
	Baseline	0.718 (0.019)	0.690 (0.029)
	Final	0.713 (0.017)	0.724 (0.030)
	Mean % change	−0.48 (1.4)	+5.05 (1.4)